EA Series Trust’s AbbVie ABBV Stock Holding History

EA Series Trust’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$3.07M	Buy	+22,797	New	+$3.34M	0.11%	263

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

EA Series Trust's ABBV Position: Q2 2023 in Review

EA Series Trust opened a new position in AbbVie (ABBV) in Q2 2023: 22,797 shares worth $3.07M. The stake represents 0.11% of the portfolio and ranks #263 among its holdings.

3,076 funds tracked by Wall St. Rank hold ABBV as of Q2 2023.

EA Series Trust held 22,797 shares of AbbVie worth $3.07M as of Q2 2023.
AbbVie was a new EA Series Trust position in Q2 2023.
AbbVie made up 0.11% of EA Series Trust's portfolio in Q2 2023, its #263 holding.
3,076 funds tracked by Wall St. Rank held AbbVie as of Q2 2023.

Based on EA Series Trust's 13F filing for Q2 2023, filed 27 Jul 2023.